Eli Lilly and Company (NYSE:LLY) to Issue $1.73 Quarterly Dividend

Posted by Geri Gentry on Jun 23rd, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) declared a quarterly dividend on Monday, June 22nd. Shareholders of record on Friday, August 14th will be given a dividend of 1.73 per share on Thursday, September 10th. This represents a c) annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th.

Eli Lilly and Company has increased its dividend by an average of 0.2%annually over the last three years and has increased its dividend every year for the last 11 years. Eli Lilly and Company has a dividend payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Eli Lilly and Company to earn $44.60 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 15.5%.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,103.69 on Tuesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a fifty day moving average of $1,019.04 and a two-hundred day moving average of $1,017.54. The company has a market cap of $1.04 trillion, a P/E ratio of 39.21, a price-to-earnings-growth ratio of 1.20 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently modified their holdings of the company. Spire Wealth Management grew its position in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after acquiring an additional 592 shares during the last quarter. Coldstream Capital Management Inc. boosted its stake in Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares during the period. Farther Finance Advisors LLC grew its position in Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its position in Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after purchasing an additional 5,595 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in shares of Eli Lilly and Company by 318.1% in the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock valued at $8,026,000 after purchasing an additional 8,003 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.